Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How should postprandial glycemia be treated?

G Charpentier1, D Dardari, J P Riveline

  • 1Service d'Endocrinologie-Diabétologie, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France. guillaume.charpentier@ch-sud-francilien.fr

Diabetes & Metabolism
|March 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump in adults and adolescents with type 1 diabetes mellitus. The SP8 trial.

Journal of endocrinological investigation·2025
Same author

Practical implementation of automated insulin delivery systems in 2025: A French position statement update.

Diabetes & metabolism·2025
Same author

Perspective of Continuous Glucose Monitoring-Based Interventions at the Various Stages of Type 2 Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2024
Same author

Early macrophage response to obesity encompasses Interferon Regulatory Factor 5 regulated mitochondrial architecture remodelling.

Nature communications·2022
Same author

Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study.

Diabetes & metabolism·2021
Same author

Practical implementation of automated closed-loop insulin delivery: A French position statement.

Diabetes & metabolism·2020

Controlling postprandial glycemia (PPG) is crucial for preventing type 2 diabetes complications. Exploring PPG treatments, like alpha-glucosidase inhibitors and GLP-1 analogs, is vital for managing daily glucose profiles.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes complications are linked to poor glycemic control.
  • Postprandial glycemia (PPG) significantly impacts HbA1c and contributes to oxidative stress and endothelial dysfunction, initiating atherogenesis.

Purpose of the Study:

  • To emphasize the importance of controlling postprandial glycemia (PPG) in type 2 diabetes management.
  • To discuss various therapeutic strategies for normalizing the daily glycemic profile.

Main Methods:

  • Review of existing antidiabetic medications and their effects on fasting blood glucose (FBG) and PPG.
  • Evaluation of the role of alpha-glucosidase inhibitors and their impact on PPG.
  • Consideration of advanced therapies like long-acting insulin analogs, GLP-1 analogs, rapid-acting insulin, and inhaled insulin for PPG management.

Related Experiment Videos

Main Results:

  • Metformin, glitazones, and insulin secretagogues affect both FBG and PPG.
  • Alpha-glucosidase inhibitors effectively reduce PPG by approximately 0.50 g/l, independent of other treatments or patient status.
  • Long-acting insulin analogs can normalize FBG but have minimal impact on PPG.

Conclusions:

  • Systematic exploration of PPG is recommended over overtreatment of FBG when oral antidiabetics fail.
  • Alpha-glucosidase inhibitors and GLP-1 analogs show promise for PPG management.
  • Advanced strategies including rapid-acting or inhaled insulin should be considered for comprehensive glycemic control in type 2 diabetes.